Skip to main navigation Skip to search Skip to main content

First-in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 765049 and BI765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solidtumors expressing B7-H6

Project: Research project

Project Details

Description

First-in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6
StatusActive
Effective start/end date2/21/24 → 2/28/34

Funding

  • BOEHRINGER-INGELHEIM PHARMACEUTICALS

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint